Message #16 From:
NewsBot Date: October 10, 2006 07:14:00 AM
SPRX News SpectRx, Inc. Director Chris Monahan Retires
NORCROSS, Ga.--(BUSINESS WIRE)--SpectRx, Inc. (OTCBB: SPRX) today announced the retirement of Director
Chris Monahan. The previously announced retirement is effective October
9, 2006. Mr. Monahan, 67, served as a Director of SpectRx, Inc. since
September 2000. A search for his successor is underway.
“Chris has been an excellent director for the
company and a mentor to me personally,” said
Mark A. Samuels, SpectRx, Inc. chairman and chief executive officer. “His
guidance and leadership will be missed. We wish him the best.”
About SpectRx, Inc.
SpectRx, Inc. (OTCBB: SPRX) is a diabetes management company developing
and providing innovative solutions for insulin delivery and glucose
monitoring. SpectRx markets the SimpleChoice®
line of innovative diabetes management products, which include insulin
pump disposable supplies. SpectRx also plans to develop a consumer
device for continuous glucose monitoring. The company is commercializing
its non-invasive cervical cancer detection technology through its
subsidiary, Guided Therapeutics, Inc., which SpectRx intends to
separately finance. For more information, visit SpectRx’s
web sites at spectrx.com, mysimplechoice.com
and guidedtherapeutics.com.
“Safe Harbor”
Statement under the Private Securities Litigation Reform Act of 1995. A
number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and
subject areas is qualified by the inherent risks and uncertainties
surrounding future expectations generally and also may materially differ
from SpectRx’s actual future experience
involving any of or more of such matters and subject areas. Such risks
and uncertainties include: the early stage of products in development,
the uncertainty of market acceptance of products, the uncertainty of
development or effectiveness of distribution channels, the intense
competition in the medical device industry, the uncertainty of capital
to develop products, the uncertainty of regulatory approval of products,
dependence on licensed intellectual property, as well as those that are
more fully described from time to time under the heading “Risk
Factors” in SpectRx’s
reports filed with the SEC, including SpectRx’s
Annual Report on Form 10-KSB for the fiscal year ended December 31,
2005, as amended, and subsequent quarterly reports.
